Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy
Acta Pharmaceutica Sinica B · 2025-06 · 15 (6) · 2845-2866
DOI: 10.1016/j.apsb.2025.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-06. Verfasst von Chenwei Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
- Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
- School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
- Institute of Chinese Materia Medical, China Academy of Chinese Medical Sciences, Beijing 100700, China.
- Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai 200240, China.
- Monyan Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201400, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Rising-Star Program
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Jiang, C., Tang, M., Su, Y., Xie, J., Shang, Q., Guo, M., An, X., Lin, L., Wang, R., Huang, Q., Zhang, G., Li, H., & Wang, F. (2025). Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B, 15(6), 2845-2866. https://doi.org/10.1016/j.apsb.2025.04.002
Vancouver
Jiang C, Tang M, Su Y, Xie J, Shang Q, Guo M, et al. Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B. 2025;15(6):2845-2866. doi:10.1016/j.apsb.2025.04.002
BibTeX
@article{Jiang2025,
author = {Jiang, Chenwei and Tang, Minglu and Su, Yun and Xie, Junjie and Shang, Qi and Guo, Mingmei and An, Xiaoran and Lin, Longfei and Wang, Ruibin and Huang, Qian and Zhang, Guangji and Li, Hui and Wang, Feihu},
title = {Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {6},
pages = {2845--2866},
doi = {10.1016/j.apsb.2025.04.002}
}
EUVIMED